Related Experiment Video
Updated: Jan 20, 2026
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Selective BRAF inhibitors make inroads in mutated metastatic melanoma
1Division of Hematology/Oncology, University of Pittsburgh, PA USA
Abstract:
The discovery that up to 50% of melanomas harbor mutations in the BRAF gene was made in 2002 and fueled the investigation into its mechanistic role as a driver mutation. BRAF mutations at the V600 position result in a constitutively active protein that underlies a classic "oncogene addiction." Since then, there have been extensive efforts to inhibit the mutated BRAF V600E/K as a therapeutic strategy. Initial attempts were made with either nonspecifc inhibitors of BRAF or with MEK inhibitors in studies that were not enriched for tumors with the BRAF mutation. The development of selective BRAF inhibitors that potently inhibit BRAF V600E/K and quench its downstream signaling revolutionized targeted therapy in melanoma. Vemurafenib was the first such agent and was developed in a phase 1 study that determined its maximally tolerated dose (MTD) to be 960 mg taken orally twice a day, and observed unprecedented tumor regression in more than 80% of patients. Those impressive results were confirmed in phase 2 and 3 studies (BRIM2 and BRIM3) and led to the drug's approval by the US Food and Drug Administration in 2011.
Insights
Targeting BRAF mutations in melanoma revolutionized treatment. Selective BRAF inhibitors, like vemurafenib, showed significant tumor regression and led to FDA approval for advanced melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Up to 50% of melanomas harbor BRAF gene mutations.
- BRAF V600 mutations create a constitutively active protein, driving oncogene addiction.
- Targeting mutated BRAF is a key therapeutic strategy in melanoma.
Purpose of the Study:
- To investigate the role of BRAF mutations as a driver in melanoma.
- To develop and evaluate targeted therapies for BRAF-mutated melanomas.
- To assess the efficacy of selective BRAF inhibitors.
Main Methods:
- Discovery of BRAF mutations in melanoma.
- Development of selective BRAF inhibitors targeting V600E/K mutations.
- Clinical trials (Phase 1, 2, and 3) to determine drug efficacy and safety.
Main Results:
- Vemurafenib, a selective BRAF inhibitor, demonstrated unprecedented tumor regression (>80%) in patients.
- Phase 1 study established the maximally tolerated dose (MTD) of vemurafenib as 960 mg twice daily.
- Phase 2 and 3 studies confirmed vemurafenib's efficacy, leading to its approval.
Conclusions:
- Targeted inhibition of BRAF V600E/K mutations represents a breakthrough in melanoma therapy.
- Selective BRAF inhibitors have revolutionized the treatment landscape for melanoma patients with these mutations.
- Vemurafenib's success paved the way for further advancements in precision oncology.
Related Concept Videos
01:39Mutations
01:35Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
00:36Viral Mutations
01:32What is Natural Selection?
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:09Mutation, Gene Flow, and Genetic Drift